|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, August 22, 2017 ) According to Publisher, the Global Anti Infective Agents Market is accounted for $83.8 billion in 2015 and expected to grow at a CAGR of 3.2% to reach $104.5 billion by 2022. Rising incidences of infectious diseases such as HIV, H1N1, and Ebola virus, awareness amongst the healthcare professionals and the patients and commercialization of pipeline products are boosting the market growth. Trends like treatment rates for communicable diseases in developing countries and treatment of Community Acquired Bacterial Pneumonia (CABP) are expected to impart the market growth. Growing resistance of infection to the drug therapies, high price of drugs, competition between generic manufacturers and perilous reimbursement policies will impede market growth.
The antibacterial segment accounted for the largest share of revenue. The anti-viral agents segment is expected to grow during the forecast period. North America commanded the anti-infective agents market and is followed by Europe. Asia Pacific is the fastest growing market due to improvements in healthcare infrastructure, demand for drugs and ongoing government initiatiatives for various control programs and strategic partnership projects.
For more information at http://www.reportsweb.com/anti-infective-agents-global-market-outlook-2016-2022 .
Some of the key players in global Anti-Infective Agents market are AstraZeneca Plc, Boehringer Ingelheim, Bristol-Myers Squibb Co, Abbott Laboratories, Bayer Healthcare AG, Cipla Ltd, Gilead Sciences,Claris Life Sciences Ltd, GlaxoSmithKline Pharmaceuticals Ltd, Merck & Co., Inc, Novartis AG, Glenmark Pharmaceuticals Ltd, Lupin Ltd, Panacea Biotech Ltd, Pfizer Ltd, Ranbaxy Laboratories Ltd, Sun Pharmaceutical Industries Ltd., Johnson & Johnson Inc., Sanofi Aventis S.A., Beijing Double-Crane Pharmaceutical Co., Ltd, Anhui Jingfang Medical Industry Co.,Ltd and Hoffman-La Roche, Inc
Products Covered:
- Antibacterial agents
o Cephalosporins
o Carbapenems
o Fluoroquinolones
o Macrolides
o Penicillins
o Clindamycin
o B-Lactam Antibiotics
o Oxazolidinones
o Aminoglycosides
o Quinolones
o Sulfonamides
o Tetracyclines
o Vancomycin
- Antifungal agents
o Azoles
o Echinocandins
o Polyenes
o Allylamines
o Macrolides derivatives
o Cresemba
- Antiviral agents
o DNA Polymerase Inhibitors
o Nucleoside Analogs
o Non-structural protein 5A (NS5A) inhibitors
o Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
o Protease Inhibitors
o Transcriptase Inhibitors
o Neuraminidase inhibitors
o Integrase strand transfer inhibitor
o Chemokine receptor antagonist
- Antituberculosis agents
o Aminosalicylates
o Diarylquinolines
o Hydrazide derivatives
o Nicotinic acid derivatives
o Rifamycin derivatives
o Streptomyces derivatives
- Vaccines
o Live/attenuated Vaccines
o Inactivated Vaccines
o DNA & Recombinant vector Vaccines
o Toxoid vaccines
- Antitreponemal agents
Request Sample Copy: http://www.reportsweb.com/inquiry&RW0001564994/sample
Regions Covered:
- North America
o US
o Canada
o Mexico
- Europe
o Germany
o France
o Italy
o UK
o Spain
o Rest of Europe
- Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o Rest of Asia Pacific
- Rest of the World
o Middle East
o Brazil
o Argentina
o South Africa
o Egypt
Make an enquiry: http://www.reportsweb.com/inquiry&RW0001564994/buying .
ReportsWeb.com
Rajat Sahni
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
